Industry
Drug Manufacturers - Specialty & Generic
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Loading...
Open
12.96
Mkt cap
1.7B
Volume
79K
High
13.09
P/E Ratio
87.10
52-wk high
15.01
Low
12.83
Div yield
N/A
52-wk low
9.74
Portfolio Pulse from
November 14, 2024 | 12:00 am
Portfolio Pulse from
November 11, 2024 | 6:15 pm
Portfolio Pulse from
November 11, 2024 | 4:15 pm
Portfolio Pulse from
November 11, 2024 | 1:15 pm
Portfolio Pulse from
November 07, 2024 | 11:45 pm
Portfolio Pulse from
November 07, 2024 | 9:15 pm
Portfolio Pulse from
November 07, 2024 | 9:15 pm
Portfolio Pulse from
November 06, 2024 | 6:30 pm
Portfolio Pulse from Benzinga Newsdesk
October 29, 2024 | 12:34 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.